Danaher Corporation $DHR Shares Sold by US Bancorp DE

Key Points

• US Bancorp DE has reduced its stake in Danaher Corporation by 4.9%, now holding approximately 570,341 shares valued at $112.67 million.
• Danaher recently announced a quarterly dividend of $0.32 per share, with an annualized dividend yield of 0.6%.
• The company reported a second-quarter EPS of $1.80, exceeding expectations, with revenue of $5.94 billion, marking a 3.4% year-over-year increase.

US Bancorp DE reduced its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 570,341 shares of the conglomerate's stock after selling 29,497 shares during the period. US Bancorp DE owned approximately 0.08% of Danaher worth $112,665,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the period. Invesco Ltd. boosted its position in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after purchasing an additional 163,332 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Down 1.7%

Shares of Danaher stock opened at $205.13 on Thursday. The firm has a market cap of $146.88 billion, a price-to-earnings ratio of 43.64, a P/E/G ratio of 2.97 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.41. The stock has a 50-day simple moving average of $200.41 and a 200-day simple moving average of $197.38.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the company earned $1.72 EPS. The firm's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Redburn Partners set a $220.00 price target on Danaher in a research report on Wednesday. Weiss Ratings restated a "hold (c-)" rating on shares of Danaher in a research report on Wednesday. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Finally, Barclays restated an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $244.60.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.